ライフサイエンスコーパス: interstitial lung disease

1 each of pneumonia, spinal cord abscess, and interstitial lung disease).

2 ulated in the setting of scleroderma-related interstitial lung disease.

3 lophosphamide), with most due to progressive interstitial lung disease.

4 tment-related by the investigator was due to interstitial lung disease.

5 ted with rheumatoid arthritis complicated by interstitial lung disease.

6 r autoantibodies, inflammatory arthritis and interstitial lung disease.

7 t role in the pathogenesis of SSc-associated interstitial lung disease.

8 or both chronic obstructive lung disease and interstitial lung disease.

9 antisynthetase syndrome and myositis-related interstitial lung disease.

10 ted for nonconnective tissue disease-related interstitial lung disease.

11 IL-22 represents a novel pathway involved in interstitial lung disease.

12 ease manifestations, including RA-associated interstitial lung disease.

13 nsion is a common and deadly complication of interstitial lung disease.

14 ngest in recipients with cystic fibrosis and interstitial lung disease.

15 patient presenting with clinical evidence of interstitial lung disease.

16 tment of pulmonary hypertension secondary to interstitial lung disease.

17 of autoantibody present and the severity of interstitial lung disease.

18 s die within 2-5 years from this progressive interstitial lung disease.

19 attenuates lung injury in a murine model of interstitial lung disease.

20 ew therapeutic approach for the treatment of interstitial lung disease.

21 ing neonatal respiratory failure and chronic interstitial lung disease.

22 even reverse, fibrogenesis in patients with interstitial lung disease.

23 hic pulmonary fibrosis, a progressive lethal interstitial lung disease.

24 hological correlates to characteristic human interstitial lung disease.

25 mast cells, than many of the other forms of interstitial lung disease.

26 of active alveolitis and scleroderma-related interstitial lung disease.

27 iarrhea, but 2% of patients died of presumed interstitial lung disease.

28 ients whose disease course is complicated by interstitial lung disease.

29 degree of activity of the systemic sclerosis-interstitial lung disease.

30 the utility of lung US SWE for evaluation of interstitial lung disease.

31 arsenic-related health effects, particularly interstitial lung disease.

32 thy subjects and study participants with any interstitial lung disease.

33 -resolution CT for noninvasive evaluation of interstitial lung disease.

34 ng abnormalities and findings suspicious for interstitial lung disease.

35 ry fibrosis (IPF) is a progressive and fatal interstitial lung disease.

36 d changes in lung physiology consistent with interstitial lung disease.

37 iques to molecularly phenotype patients with interstitial lung disease.

38 may facilitate investigation of subclinical interstitial lung disease.

39 temic steroids, and 1 patient died of severe interstitial lung disease.

40 inflammation, destructive skin lesions, and interstitial lung disease.

41 that may play a role in the pathogenesis of interstitial lung diseases.

42 nts as chronic respiratory illness mimicking interstitial lung diseases.

43 to be a useful marker of disease activity in interstitial lung diseases.

44 er iBALT forms in patients with a variety of interstitial lung diseases.

45 and understanding of the pathogenesis of the interstitial lung diseases.

46 e fluid similar to other CD8 T cell-mediated interstitial lung diseases.

47 singly recognized as a complication of these interstitial lung diseases.

48 e proportion of rheumatic disease-associated interstitial lung diseases.

49 t concepts regarding the management of these interstitial lung diseases.

50 results regarding diagnosis and prognosis in interstitial lung diseases.

51 Lung fibrosis is the hallmark of the interstitial lung diseases.

52 .8%), idiopathic pulmonary fibrosis (22.9%), interstitial lung disease (15.6%), and cystic fibrosis (

53 D, 360; alpha-1-antitrypsin deficiency, 127; interstitial lung disease, 195; cystic fibrosis, 69; oth

54 ive patient with Blau syndrome who exhibited interstitial lung disease, a feature historically consid

55 In other conditions, such as tuberculosis, interstitial lung disease, acute lung aspiration, and ac

56 Patients with interstitial lung disease aged between 18 and 80 years w

57 Plains, New England, and South Atlantic for interstitial lung disease; along the southern half of th

58 due to telomere dysfunction and humans with interstitial lung disease also accumulate excess chitin

59 ge, 43 [16] years) including 4 patients with interstitial lung disease and 3 patients with cutaneous

60 ge, 43 [16] years) including 4 patients with interstitial lung disease and 3 patients with cutaneous

61 rd deviation [SD], 62.4 years +/- 12.9) with interstitial lung disease and 30 healthy subjects (women

62 retrospective analysis of all patients with interstitial lung disease and acute respiratory failure

63 Patients with interstitial lung disease and acute respiratory failure

64 CMO is a lifesaving option for patients with interstitial lung disease and acute respiratory failure

65 An association between calcinosis and both interstitial lung disease and anti-MDA-5 autoantibodies

66 ation in the human ITGA3 gene, causing fatal interstitial lung disease and congenital nephrotic syndr

67 Patients were undergoing evaluation for interstitial lung disease and had had samples obtained b

68 plinary committee of experts in the field of interstitial lung disease and HP using the GRADE (Gradin

69 apeutic strategies in scleroderma-associated interstitial lung disease and in idiopathic pulmonary fi

70 rfactant proteins are found in patients with interstitial lung disease and lung cancer, but their pat

71 important factor in the pathogenesis of the interstitial lung disease and lymphoproliferative disord

72 idence in the multidisciplinary diagnosis of interstitial lung disease and may prove useful in the di

73 (aSS) is characterized by the association of interstitial lung disease and myositis with anti-tRNA sy

74 study drug by the investigators, one due to interstitial lung disease and one as a result of multior

75 ted: two in the nivolumab group (one each of interstitial lung disease and pneumonitis) and three in

76 Pulmonary diseases, comprising interstitial lung disease and pulmonary arterial hyperte

77 n the chemotherapy plus cetuximab group (one interstitial lung disease and pulmonary embolism, one br

78 ational Classification of Diseases codes for interstitial lung disease and surgical lung biopsies.

79 variety of pulmonary diseases including the interstitial lung diseases and asthma.

80 nary fibrosis is the most common form of the interstitial lung diseases and is characterized by chron

81 D-208 may be therapeutically useful in human interstitial lung diseases and pulmonary fibrosis.

82 f gene expression signatures to classify the interstitial lung diseases and to understand pathogenic

83 m-223 group (acute myocardial infarction and interstitial lung disease) and one (<1%) in the placebo

84 clerosis-related pulmonary hypertension with interstitial lung disease, and 67 IPAH).

85 osis, chronic obstructive pulmonary disease, interstitial lung disease, and coronary artery disease.

86 d to pulmonary hypertension in patients with interstitial lung disease, and effective treatment optio

87 that included congenital nephrotic syndrome, interstitial lung disease, and epidermolysis bullosa.

88 system represents a new model of autoimmune interstitial lung disease, and establishes a closer link

89 sculopathy, he experienced recurrent fevers, interstitial lung disease, and failure to thrive.

90 stitial pneumonia, respiratory bronchiolitis-interstitial lung disease, and from patients without IIP

91 grade 3 abdominal pain, colitis, hepatitis, interstitial lung disease, and jaundice, and grade 4 cho

92 mofetil for progressive scleroderma-related interstitial lung disease, and the present preference fo

93 into the causes of other forms of pediatric interstitial lung diseases, and may suggest novel treatm

94 on of a "pulmonary-muscle" syndrome in which interstitial lung disease antedated the onset of myopath

95 -section CT findings usually associated with interstitial lung disease are frequently seen in asympto

96 studies of systemic sclerosis patients with interstitial lung disease are yielding promising data th

97 The interstitial lung diseases are a heterogeneous group of

98 Children's interstitial lung diseases are rare diffuse lung disease

99 atous glomerular and interstitial nephritis, interstitial lung disease, arterial hypertension, hypert

100 thic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease associated with aging that is

101 ry lymphoneogenesis, although a component of interstitial lung disease associated with autoimmune dis

102 cal spectrum, pathogenesis, and treatment of interstitial lung disease associated with inflammatory m

103 Whether the prognosis of interstitial lung disease associated with rheumatic dise

104 rs predict in-hospital mortality in fibrotic interstitial lung disease-associated mechanical ventilat

105 eature of numerous lung disorders, including interstitial lung diseases, asthma, and chronic obstruct

106 There was a basilar predominance of interstitial lung disease at CT.

107 ng biopsy samples from patients with various interstitial lung diseases at 11 hospitals in North Amer

108 th chronic obstructive pulmonary disease and interstitial lung disease but not cancer.

109 odies were also found in patients with other interstitial lung diseases but were not associated with

110 ial pneumonia, and respiratory bronchiolitis-interstitial lung disease, but not patients without IIP,

111 y a role in the etiology and pathogenesis of interstitial lung disease, but transcriptional signature

112 ate the investigation of pathologies such as interstitial lung disease, cancer and coronavirus diseas

113 75% predicted) conducted in 39 UK specialist interstitial lung disease centers between April 2015 (fi

114 study done at 65 pulmonary hypertension and interstitial lung disease centres in 19 countries to eva

115 Interstitial lung disease characteristics, demographics,

116 Lymphangioleiomyomatosis (LAM) is an interstitial lung disease characterized by invasion and

117 These autoimmune mice had interstitial lung disease characterized by lymphocytic a

118 nary fibrosis (IPF) is a chronic progressive interstitial lung disease characterized by patchy scarri

119 Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by severe, progr

120 Childhood interstitial lung disease (chILD) comprises a spectrum o

121 endous progress in the approach to childhood interstitial lung diseases (chILD), with particular reco

122 at our institution between 2004 and 2014 for interstitial lung disease, chronic obstructive pulmonary

123 In addition to the historical interstitial lung diseases (coal worker's pneumoconiosis

124 of lung fibrosis and in human subjects with interstitial lung disease compared to that in control he

125 onitis, respiratory bronchiolitis-associated interstitial lung disease, cryptogenic organizing pneumo

126 were similar to the 221 patients with other interstitial lung disease diagnoses (1.46 [0.24]) after

127 -0.63]; p=0.0048), but not for patients with interstitial lung disease diagnoses other than idiopathi

128 Interstitial lung disease diagnosis negatively predicted

129 novel technique for sampling lung tissue for interstitial lung disease diagnosis.

130 data support the clinical utility of TBLC in interstitial lung disease diagnostic algorithms.

131 Pulmonary fibrosis is a kind of devastating interstitial lung disease due to the limited therapeutic

132 eatment for systemic sclerosis (SSc)-related interstitial lung disease, elicits a disease-modifying e

133 Interstitial lung diseases encompass a wide range of dif

134 ects (F0) and participants with any grade of interstitial lung disease (F1-F3).

135 Establishing the etiology of fibrosing interstitial lung disease (FILD) remains a clinical chal

136 the recent medical literature pertaining to interstitial lung disease found in association with syst

137 Interstitial lung disease frequently complicates the rhe

138 Forty-five experts in interstitial lung disease from 14 countries participated

139 onal cohort study, we enrolled patients with interstitial lung disease from Dallas, TX (primary cohor

140 iciency (CVID) and granulomatous/lymphocytic interstitial lung disease (GLILD) are at high risk for e

141 Granulomatous and lymphocytic interstitial lung disease (GLILD) is a life-threatening

142 and a specificity of 81% for differentiating interstitial lung disease grades F0-F2 from F3.

143 The extent of interstitial lung disease, ground-glass opacification, e

144 atients with symptomatic scleroderma-related interstitial lung disease had a significant but modest b

145 Patients with SSc in whom PH and significant interstitial lung disease had been excluded at baseline

146 trials in patients with myositis-associated interstitial lung disease have not occurred, new observa

147 Diagnosis is difficult because other interstitial lung diseases have similar radiological and

148 high-throughput flow cytometry (FC) data and interstitial lung disease (ILD) - a systemic sclerosis (

149 and to determine progression toward clinical interstitial lung disease (ILD) among subjects in a long

150 The mechanisms underlying dyspnea in interstitial lung disease (ILD) and chronic obstructive

151 ssification (DPO) in patients with fibrosing interstitial lung disease (ILD) and determine whether th

152 omography (CT) is prevalent in patients with interstitial lung disease (ILD) and may reflect immunolo

153 the most pressing challenges associated with interstitial lung disease (ILD) are how best to define,

154 biopsy (SLB) as the current gold standard-in interstitial lung disease (ILD) cases requiring histolog

155 mon and specific signatures across end-stage interstitial lung disease (ILD) cases, (2) characterize

156 onary fibrosis (IPF) is a progressive, fatal interstitial lung disease (ILD) characterized by abnorma

157 n the lung tissue of patients suffering from interstitial lung disease (ILD) due to mutations in the

158 he diagnosis and management of patients with interstitial lung disease (ILD) has been a subject of de

159 Interstitial lung disease (ILD) has been recognized as a

160 onavirus disease (COVID-19) on patients with interstitial lung disease (ILD) has not been established

161 nge of occupational exposures on subclinical interstitial lung disease (ILD) has not been studied.

162 e prevalence and clinical characteristics of interstitial lung disease (ILD) in a large cohort of pat

163 actant protein C; SFTPC) have been linked to interstitial lung disease (ILD) in children and adults.

164 tion, diagnosis, treatment, and prognosis of interstitial lung disease (ILD) in children.

165 es (chILD), with particular recognition that interstitial lung disease (ILD) in infants is often dist

166 and understanding of the entities that cause interstitial lung disease (ILD) in infants.

167 Interstitial lung disease (ILD) is a common manifestatio

168 RATIONALE: Interstitial lung disease (ILD) is a heterogeneous group

169 Interstitial lung disease (ILD) is a well-known extra-ar

170 tatins) in the development or progression of interstitial lung disease (ILD) is controversial.

171 Interstitial lung disease (ILD) is fast approaching chro

172 Interstitial lung disease (ILD) is the leading cause of

173 n systemic sclerosis (SSc; scleroderma), and interstitial lung disease (ILD) is the most common pulmo

174 ic pulmonary fibrosis (IPF) is a progressive interstitial lung disease (ILD) of unknown origin charac

175 he automatic identification of more advanced Interstitial Lung Disease (ILD) patterns, few have tackl

176 Rationale: Interstitial lung disease (ILD) represents a major chall

177 Interstitial lung disease (ILD) with pulmonary fibrosis

178 Interstitial lung disease (ILD), a leading cause of morb

179 hronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), and "other." Intensive

180 cal role in systemic sclerosis (SSc)-related interstitial lung disease (ILD), and imatinib is a poten

181 ructive pulmonary disease (COPD), asthma and interstitial lung disease (ILD), and individual cardiova

182 fibrosis (FPF) are at an increased risk for interstitial lung disease (ILD), the risk among relative

183 cy in myositis including those patients with interstitial lung disease (ILD), whereas mycophenolate m

184 cotherapies are available for unclassifiable interstitial lung disease (ILD), which is characterised

185 pathway are important in the pathogenesis of interstitial lung disease (ILD).

186 rved in patients with clinically significant interstitial lung disease (ILD).

187 sociated with cancer, neurodegeneration, and interstitial lung disease (ILD).

188 l hypertension [PAH]) or in association with interstitial lung disease (ILD).

189 including mortality, even in the absence of Interstitial Lung Disease (ILD).

190 tor antagonist, as a therapy for SSc-related interstitial lung disease (ILD).

191 erial hypertension [PAH]) or associated with interstitial lung disease (ILD).

192 ng function in patients with scleroderma and interstitial lung disease (ILD).

193 sitis/dermatomyositis (PM/DM) complicated by interstitial lung disease (ILD).

194 nts with SSc; 25% to 30% develop progressive interstitial lung disease (ILD).

195 ase that presents as pulmonary hemorrhage or interstitial lung disease (ILD).

196 ies (ROS) are implicated in the aetiology of interstitial lung disease (ILD).

197 whether this association is attributable to interstitial lung disease (ILD).

198 nic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD).Methods: The multidiscip

199 SMR, 2.1), infections (EAR, 10.6; SMR, 3.9), interstitial lung disease (ILD; EAR, 9.7; SMR, 22.1), an

200 The rate of progression of most interstitial lung diseases (ILD) is unpredictable.

201 Interstitial lung diseases (ILDs) are associated with ox

202 Progressive fibrotic interstitial lung diseases (ILDs) are characterised by m

203 Interstitial lung diseases (ILDs) are characterized by i

204 Background Longitudinal follow-up of interstitial lung diseases (ILDs) at CT mainly relies on

205 of chronic lung diseases such as asthma and interstitial lung diseases (ILDs), including idiopathic

206 clerosis-related pulmonary hypertension with interstitial lung disease imposes a greater pulmonary va

207 t radiography and CT, respectively, revealed interstitial lung disease in 47 (90%) and 51 (98%) of th

208 ause lethal respiratory distress at birth or interstitial lung disease in childhood.

209 the development of granulomatous-lymphocytic interstitial lung disease in CVID), and an increased ris

210 Mutations in the SFTPC gene associated with interstitial lung disease in human patients result in mi

211 s of alveolar hemorrhage as the mechanism of interstitial lung disease in MPA.

212 l-transfer RNA synthetase (HisRS, Jo-1) with interstitial lung disease in patients with myositis led

213 Interstitial lung disease in patients with SSc is less e

214 s of morphologic and functional worsening of interstitial lung disease in patients with systemic scle

215 ABCA3 mutations cause some types of interstitial lung disease in pediatric patients.

216 Several histologic lesions cause interstitial lung disease in rheumatic diseases, includi

217 whether this polymorphism is associated with interstitial lung disease in the general population.

218 polymorphism was found to be associated with interstitial lung disease in the general population.

219 g of the phenotype and prognosis that define interstitial lung disease in the setting of myositis and

220 urgical lung biopsies performed annually for interstitial lung disease in the United States, two-thir

221 rosis (IPF) is a fatal and incurable form of interstitial lung disease in which persistent injury res

222 suggested a genetic basis for some forms of interstitial lung diseases in children.

223 ne encoding SP-C are associated with chronic interstitial lung diseases in newborns, older children,

224 shes usual interstitial pneumonia from other interstitial lung diseases in surgical lung biopsy sampl

225 onchiolar involvement may be seen in several interstitial lung diseases, including hypersensitivity p

226 The pathogenesis of interstitial lung diseases, including its most common fo

227 y, subacute and chronic HP may mimic several interstitial lung diseases, including nonspecific inters

228 of normal adult lung or other proliferative interstitial lung diseases, indicating that the expressi

229 BCA3, have been shown to result in pediatric interstitial lung diseases inherited in autosomal-domina

230 le: Declining lung function in patients with interstitial lung disease is accompanied by epithelial r

231 Interstitial lung disease is common in the rheumatic dis

232 lity after elective surgical lung biopsy for interstitial lung disease is just under 2% but significa

233 Respiratory bronchiolitis-interstitial lung disease is now commonly diagnosed with

234 ary fibrosis (IPF), a fatal and irreversible interstitial lung disease, is predicted by the circulati

235 0.77]) and connective tissue disease-related interstitial lung disease (kappaw=0.73 [0.68-0.78]); mod

236 - mice, a strain that spontaneously develops interstitial lung disease-like lung pathology with age.

237 and other diseases (asthma, smoking-related interstitial lung diseases) linked to OPN overexpression

238 mon serious adverse events were worsening of interstitial lung disease (main study: six [8%] of 73 in

239 US medical centres with scleroderma-related interstitial lung disease meeting defined dyspnoea, pulm

240 dyspnoea (n=1), failure to thrive (n=1), and interstitial lung disease (n=1).

241 s in the carfilzomib group (pneumonia [n=2], interstitial lung disease [n=1], septic shock [n=1], and

242 ns with nonconnective tissue disease-related interstitial lung disease (nCTD-ILD).

243 SV hospitalization, including malformations, interstitial lung disease, neuromuscular disease, liver

244 Four patients developed interstitial lung disease of grade 3 or higher, with one

245 Idiopathic pulmonary fibrosis is a chronic interstitial lung disease of unknown etiology; its epide

246 sis (IPF) is a progressive and heterogeneous interstitial lung disease of unknown origin with a low s

247 ology, dyspnea, and evidence of inflammatory interstitial lung disease on examination of bronchoalveo

248 ed ILC populations, regardless of diagnosis (interstitial lung disease or chronic obstructive pulmona

249 s with COPD, alpha-1-antitrypsin deficiency, interstitial lung disease, or cystic fibrosis before and

250 ook place in the management of patients with interstitial lung diseases over the last century.

251 cardiac arrest, dehydration, hepatotoxicity, interstitial lung disease, pancytopenia, and sepsis [n=1

252 on in the pathogenesis of systemic sclerosis-interstitial lung disease, particularly in the early pha

253 s on developing safe and effective drugs for interstitial lung diseases, particularly for idiopathic

254 oproteinase-7 (MMP-7) has been implicated in interstitial lung disease pathobiology and proposed as a

255 nti-inflammatory mediators may be central to interstitial lung disease pathogenesis, which presents p

256 tial pneumonia and respiratory bronchiolitis/interstitial lung disease patient groups.

257 haracteristics of a large cohort of fibrotic interstitial lung disease patients from the perspective

258 ies report significant mortality in fibrotic interstitial lung disease patients undergoing mechanical

259 Investigators reported 20 cases of interstitial lung disease, pneumonitis, or organising pn

260 ification of genes responsible for pediatric interstitial lung diseases provides the opportunity for

261 n-group difference in change in King's Brief Interstitial Lung Disease Questionnaire (K-BILD) score a

262 cester Cough Questionnaire, and King's Brief Interstitial Lung Disease questionnaire scores).

263 (DIP), respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), cryptogenic organizi

264 disciplinary discussion (MDD), patients with interstitial lung disease referred for lung biopsy under

265 Forty patients with interstitial lung disease referred to our intensive care

266 osis pathogenesis, a chronic and progressive interstitial lung disease, remain elusive.

267 Many of the interstitial lung diseases represent a diagnostic and th

268 lung abnormality and findings suspicious for interstitial lung disease, respectively.

269 t with early-onset systemic inflammation and interstitial lung disease, resulting in pulmonary fibros

270 unrelated families and 44 sporadic cases of interstitial lung disease revealed five other mutations

271 atistically significant correlations between interstitial lung disease score at CT and age or percent

272 Treatment of these interstitial lung diseases should take into account the

273 l lymphoproliferative disorders, infections, interstitial lung diseases, smoking, and congenital or d

274 Patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) are thought to have

275 onary fibrosis (IPF) and scleroderma-related interstitial lung disease (SSc-ILD).

276 patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

277 , chronic obstructive pulmonary disease, and interstitial lung diseases such as idiopathic pulmonary

278 There was less HRQL benefit in interstitial lung disease than in cystic fibrosis.

279 Hypersensitivity pneumonitis is an interstitial lung disease that results from repeated pul

280 in chronic obstructive pulmonary disease or interstitial lung disease transplant recipients is assoc

281 ions between the diagnosis of obstructive or interstitial lung disease, two diagnostic breathing test

282 inflammation characterized by vasculopathy, interstitial lung disease, ulcerative skin lesions, and

283 inical data of patients who presented to the interstitial lung disease unit of the Royal Brompton and

284 Interstitial lung disease was common and was equally dis

285 A score for the degree of interstitial lung disease was derived at both radiograph

286 Severity of interstitial lung disease was graded as none (healthy lu

287 2 of 16 SRP-positive PM patients (13%), and interstitial lung disease was noted in 3 of 13 SRP-posit

288 ophosphamide for treatment of SSc-associated interstitial lung disease were evaluated.

289 ibrosis or connective tissue disease-related interstitial lung disease were risk factors for increase

290 alter the progression of scleroderma-related interstitial lung disease when compared with placebo.

291 fibrosis (IPF) is a chronic and progressive interstitial lung disease, wherein transforming growth f

292 sclerosis or limited systemic sclerosis and interstitial lung disease who were treated with HSCT as

293 ssive intervention in African Americans with interstitial lung disease will improve outcomes.

294 ic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with a median survival of 3 ye

295 Treatment of scleroderma-related interstitial lung disease with mycophenolate mofetil for

296 a common, progressive, and invariably lethal interstitial lung disease with no effective therapy.

297 nary fibrosis (IPF) is a form of progressive interstitial lung disease with unknown etiology.

298 he occurrence of familial cases of pediatric interstitial lung diseases with the onset of symptoms de

299 s, infections, smoking-related diseases, and interstitial lung diseases, with a focus on lymphangiole

300 study we selected 117 patients with fibrotic interstitial lung disease without a typical usual inters